FDA has approved the CDK4/6 inhibitor abemaciclib (Verzenio) as a first-line treatment in some women with advanced or metastatic breast cancer. Under the approval, the drug must be used in combination with an aromatase inhibitor.
from Cancer via ola Kala on Inoreader http://ift.tt/2G8w9lZ
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου